NCT06663631Toboroz1. fázis
Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
The Safety and effiCacy of HIbernation-Like Therapy Combining recanaLization in Ischemic Stroke: a Phase 1, Dose-escalation Study
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2024. dec. 20. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
The goal of this clinical trial is to learn whether chlorpromazine and promethazine(C+P)is safe in Acute Ischemic Stroke(AIS) patients and determine the maximum dosage. It will also evaluate the preliminary efficacy of C+P in AIS. The main questions it aims to answer are: What is the optimal dosage of C+P that is safe without causing adverse effects in AIS patients? What is the optimal dosage of C+P that potentially works to treat AIS? Researchers will compare C+P with placebo (saline solution without C+P) to see if C+P is safe and effective in treating Acute Ischemic Stroke. Participants will: Receive C+P or placebo at the same time as endovascular thrombectomy begins. Patients will be observed for 72 hours to see if there were any adverse effects related to C+P. Infarct volumes will be evaluated using Computed Tomography. Functional outcomes will be assessed at 90 days.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 32 (tervezett)
- Első benyújtás
- 2024. okt. 24.
- Kezdés
- 2024. nov. 9.
- Elsődleges befejezés
- 2025. jan.
- Fő szponzor
- Capital Medical University
- Betegségek
- Stroke (szélütés)
- NCT-szám
- NCT06663631
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1. fázis
- Tervezett résztvevők: 32
- 2024. nov. 9. és az elsődleges befejezés (2025. jan.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Image exclusion criteria:
- computed tomographic angiography(CTA)/magnetic resonance angiography(MRA)/digital substraction angiography(DSA) shows excessive vascular curvature, which may hinder delivery of interventional devices
- Cerebrovascular inflammation is suspected based on medical history and CTA/MRA/DSA
- Aortic dissection is suspected based on medical history and CTA/MRA/DSA
- CTA/MRA/DSA confirmed multi-vascular regional occlusion (such as bilateral anterior circulation or anterior/posterior circulation, extracranial carotid artery with intracranial tandem lesions), or clinical evidence of bilateral or multi-regional infarction
- CTA/MRA/DSA confirms moyamoya disease or moyamoya syndrome
- CT/MRI confirmed a significant midline shift effect
- CT/MRI confirms the presence of intracranial tumors (except cerebellar meningioma) CT/MRI confirmed intracranial hemorrhage
Laborértékek
- Clinical Exclusion Criteria:
- Clinical findings suggest intracranial parenchymal hemorrhage or subarachnoid hemorrhage.
- Accompanied by epilepsy.
- Accompanied by coma or mental disorders, may interfere with neurological function assessment.
- History of premorbid phenothiazine allergy or contraindication.
- History of allergy to iodine contrast medium or anaphylactic shock
- Baseline blood glucose <50mg/dL (2.78mmol) or >400mg/dL (22.20mmol)
- Acceptable fingertip blood glucose results
- Baseline platelet <50×109 /L
- Recent (i.e. within 30 days prior to randomization) history of gastrointestinal or other clinically significant bleeding; Active bleeding, abnormal clotting factors, or bleeding tendency (INR≥3 or PT≥3×ULN on anticoagulants; If the investigator believes that the subject does not have coagulation dysfunction, it is not necessary to wait for the results of the coagulation test before deciding whether to enroll.)
- The stroke is accompanied by fever, or there is an active infection requiring systemic treatment (such as active tuberculosis, etc.)
- Expected survival less than 90 days (According to the Chinese Guidelines for Early Endovascular Interventional Diagnosis and Treatment of Acute Ischemic Stroke 2022, expected survival less than 90 days is a contraindication for endovascular therapy)
- A history of severe cardiovascular disease, including but not limited to: uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg after standard treatment), hypotension (systolic blood pressure ≤100 mmHg after standard treatment), or pulmonary hypertension; Had unstable angina pectoris, myocardial infarction, or bypass or stent surgery within 6 months before randomization; New York Heart Association (NYHA) grade 3-4 history of chronic heart failure; Clinically significant valvular disease; Severe arrhythmias requiring treatment (except atrial fibrillation and paroxysmal supraventricular tachycardia), including QT interval ≥450ms for men and ≥470ms for women
- accompanied by chronic obstructive pulmonary disease(COPD), tuberculosis, pneumonia, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, pleural effusion, acute respiratory distress syndrome, respiratory irregularity and other lung diseases
- Severe hepatic and renal insufficiency, including but not limited to: cirrhosis, hepatic encephalopathy, ascites, renal failure or uremia (Ccr<25ml/min), hepatorenal syndrome, etc
- Pregnancy or lactating women
- Participation in other clinical trials and have used an investigational drug or medical device
- Patients that may not be able to complete the study for other reasons or who the investigator believes should not be included
Kiket keres a vizsgálat
- Clinical Inclusion Criteria:
- Age between 18-80 years(including the critical value)
- Ischemic stroke with a National Institutes of Health Stroke Scale (NIHSS) score ranging from 6-20
- Time from last known to be well to randomization within 24h
- Pre-stroke Modified Rankin Scale scoring 0-1.
- With indications of reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy).
- Informed consent signed by patients or their legal relatives.
- CT angiography (CTA) confirmed large vessel occlusion of anterior circulation
- Alberta Stroke Program Early Computed Tomography Score (ASPECT) score of 6-10.
- initial infarct volume on CT perfusion (CTP) lesser than 70ml; a ratio of hypoperfused volume to infarcted volume greater than 1.8; absolute mismatch volume greater than 15 ml according to DEFUSE-3 trial.
Életkor a regiszterben: 18 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Linyi People's Hospital | Linyi | Kína | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.